Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 Nov 22

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 Nov 22

DOI: 10.23736/S1824-4785.17.03038-2

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Advances in oncological treatment: limitations of RECIST 1.1 criteria

Serena GRIMALDI 1 , Marie TERROIR 1, Caroline CARAMELLA 2

1 Department of Nuclear Medicine and Endocrine Tumors, Gustave Roussy Institute, Villejuif, France; 2 Department of Radiology, Gustave Roussy Institute, Villejuif, France


PDF  


INTRODUCTION: RECIST 1.1 criteria are the standard for the response assessment of most solid tumors on computed tomography (CT). Nevertheless, the emergence of new classes of treatment in the lasts decades has brought new challenges in the response evaluation.
EVIDENCE ACQUISITION: A PubMed online database literature search was performed in order to identify papers in English with full text available published up to September 2017.
EVIDENCE SYNTHESIS: Some oncologic treatments, such as anti-angiogenic agents, immunotherapy and local treatments, have proven to be effective despite atypical patterns of responses. In patients undergoing these treatments, size-based evaluations, such as RECIST1.1, showed some limitations, since they often underestimate the response. Some modified criteria have been proposed to improve the response assessment in several specific settings, such in gastro-intestinal stromal tumors treated by anti-angiogenic agents, hepatocellular carcinoma treated by local ablation or solid tumors treated by immunotherapy. New techniques of image analysis and imaging modalities other than CT, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), may provide additional information and mend some limitation of size-based criteria.
CONCLUSIONS: The emergence of new treatment paradigms and the increasing trend toward personalizing treatment should be associated with a concomitant evolution of response assessment, in both research and clinical settings.


KEY WORDS: RECIST - Response criteria - Anti-angiogenic - Immunotherapy - Loco-regional treatment

inizio pagina

Publication History

Article first published online: November 22, 2017
Manuscript accepted: November 7, 2017
Manuscript received: October 13, 2017

Per citare questo articolo

Grimaldi S, Terroir M, Caramella C. Advances in oncological treatment: limitations of RECIST 1.1 criteria. Q J Nucl Med Mol Imaging 2017 Nov 22. DOI: 10.23736/S1824-4785.17.03038-2

Corresponding author e-mail

serena.grimaldi@gustaveroussy.fr